Lyra Therapeutics: Funding, Investors & Team (Sep 2026)
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
Lyra Therapeutics has raised $101M across 1 funding round on record, the most recent a Post-IPO Equity of $101M announced in Apr 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lyra Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Lyra Therapeutics Funding Rounds
Lyra Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Lyra Therapeutics Funding Compared to Other Biotechnology Startups
Lyra Therapeutics' latest round of $101M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lyra Therapeutics in Biotechnology and Watertown
Companies Similar to Lyra Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Lyra Therapeutics Funding FAQs
What does Lyra Therapeutics do?
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of CRS. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate, which is the active ingredient in various FDA-approved drugs and has a well-established efficacy and safety profile.
How much funding has Lyra Therapeutics raised?
Lyra Therapeutics has raised $101M across 1 round on record. The most recent is a Post-IPO Equity of $101M announced in Apr 2022.
When did Lyra Therapeutics last raise funding?
Lyra Therapeutics' most recent funding round on record is a Post-IPO Equity of $101M, announced in Apr 2022.
Who is the CEO of Lyra Therapeutics?
Maria Palasis is listed as CEO at Lyra Therapeutics.
Where is Lyra Therapeutics headquartered?
Lyra Therapeutics is based in Watertown, Massachusetts, United States.
How many employees does Lyra Therapeutics have?
Lyra Therapeutics is in the 51-100 employee band.
How does Lyra Therapeutics' funding compare to other Biotechnology startups?
Lyra Therapeutics' latest round of $101M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Lyra Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lyra Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.